Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

MAU868

Monoclonal antibody · Antagonist of BK polyomavirus VP1 · developed by Vera Therapeutics

Phase 2 Most advanced trial (none active)

VERA Developer

1 Registered trials

What is MAU868?

MAU868 is a human monoclonal antibody (IgG1) that binds to BK polyomavirus VP1, the viral capsid protein responsible for host cell binding. It is studied in BK virus infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: BK polyomavirus VP1
Mechanism: Antagonist of BK polyomavirus VP1
Therapy area: Infectious disease
Developer: Vera Therapeutics, Inc. (VERA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: V5T95AZA8Y

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04294472	Phase 2	BK Virus Infection	Completed	VERA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

BK Virus Infection

More from Vera Therapeutics

Atacicept FDA approved

Sources

ClinicalTrials.gov NCT04294472

Updated Oct 3, 2026. Something wrong or missing? Report it on the VERA page.

Follow VERA, the company behind MAU868

See VERA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VERA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z